227 related articles for article (PubMed ID: 31369181)
1. Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up.
Murali N; Browne RW; Fellows Maxwell K; Bodziak ML; Jakimovski D; Hagemeier J; Bergsland N; Weinstock-Guttman B; Zivadinov R; Ramanathan M
Eur J Neurol; 2020 Jan; 27(1):188-e4. PubMed ID: 31369181
[TBL] [Abstract][Full Text] [Related]
2. Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis.
McComb M; Parambi R; Browne RW; Bodziak ML; Jakimovski D; Bergsland N; Maceski A; Weinstock-Guttman B; Kuhle J; Zivadinov R; Ramanathan M
Mult Scler Relat Disord; 2020 Oct; 45():102389. PubMed ID: 32683305
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol pathway biomarkers are associated with neuropsychological measures in multiple sclerosis.
Siddiqui K; Browne RW; Benedict RHB; Jakimovski D; Weinstock-Guttman B; Zivadinov R; Ramanathan M
Mult Scler Relat Disord; 2023 Jan; 69():104374. PubMed ID: 36403378
[TBL] [Abstract][Full Text] [Related]
4. High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis.
Jakimovski D; Zivadinov R; Dwyer MG; Bergsland N; Ramasamy DP; Browne RW; Weinstock-Guttman B; Ramanathan M
J Neurol Sci; 2020 Nov; 418():117120. PubMed ID: 32947088
[TBL] [Abstract][Full Text] [Related]
5. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort.
Mariosa D; Hammar N; Malmström H; Ingre C; Jungner I; Ye W; Fang F; Walldius G
Ann Neurol; 2017 May; 81(5):718-728. PubMed ID: 28437840
[TBL] [Abstract][Full Text] [Related]
6. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
Eijlers AJC; van Geest Q; Dekker I; Steenwijk MD; Meijer KA; Hulst HE; Barkhof F; Uitdehaag BMJ; Schoonheim MM; Geurts JJG
Brain; 2018 Sep; 141(9):2605-2618. PubMed ID: 30169585
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis.
McComb M; Krikheli M; Uher T; Browne RW; Srpova B; Oechtering J; Maceski AM; Tyblova M; Jakimovski D; Ramasamy DP; Bergsland N; Krasensky J; Noskova L; Fialova L; Weinstock-Guttman B; Havrdova EK; Vaneckova M; Zivadinov R; Horakova D; Kuhle J; Ramanathan M
J Clin Lipidol; 2020; 14(5):675-684.e2. PubMed ID: 32758395
[TBL] [Abstract][Full Text] [Related]
8. Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study.
Browne RW; Weinstock-Guttman B; Zivadinov R; Horakova D; Bodziak ML; Tamaño-Blanco M; Badgett D; Tyblova M; Vaneckova M; Seidl Z; Krasensky J; Bergsland N; Ramasamy DP; Hagemeier J; Qu J; Havrdova E; Ramanathan M
J Steroid Biochem Mol Biol; 2014 Sep; 143():424-33. PubMed ID: 24950029
[TBL] [Abstract][Full Text] [Related]
9. Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.
Uher T; Fellows K; Horakova D; Zivadinov R; Vaneckova M; Sobisek L; Tyblova M; Seidl Z; Krasensky J; Bergsland N; Weinstock-Guttman B; Havrdova E; Ramanathan M
J Lipid Res; 2017 Feb; 58(2):403-411. PubMed ID: 27923871
[TBL] [Abstract][Full Text] [Related]
10. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects.
Hughes TA; Stentz F; Gettys T; Smith SR
Metabolism; 2006 Jan; 55(1):26-34. PubMed ID: 16324916
[TBL] [Abstract][Full Text] [Related]
11. Cortical Perfusion Alteration in Normal-Appearing Gray Matter Is Most Sensitive to Disease Progression in Relapsing-Remitting Multiple Sclerosis.
Hojjat SP; Kincal M; Vitorino R; Cantrell CG; Feinstein A; Zhang L; Lee L; O'Connor P; Carroll TJ; Aviv RI
AJNR Am J Neuroradiol; 2016 Aug; 37(8):1454-61. PubMed ID: 27012299
[TBL] [Abstract][Full Text] [Related]
12. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP;
J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584
[TBL] [Abstract][Full Text] [Related]
13. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.
Walldius G; Jungner I; Aastveit AH; Holme I; Furberg CD; Sniderman AD
Clin Chem Lab Med; 2004; 42(12):1355-63. PubMed ID: 15576296
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal changes of deep gray matter shape in multiple sclerosis.
Tsagkas C; Geiter E; Gaetano L; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Kappos L; Sprenger T; Granziera C; Mallar Chakravarty M; Magon S
Neuroimage Clin; 2022; 35():103137. PubMed ID: 36002960
[TBL] [Abstract][Full Text] [Related]
15. Antioxidant defense enzymes in multiple sclerosis: A 5-year follow-up study.
Essenburg C; Browne RW; Ghazal D; Tamaño-Blanco M; Jakimovski D; Weinstock-Guttman B; Zivadinov R; Ramanathan M
Eur J Neurol; 2023 Aug; 30(8):2338-2347. PubMed ID: 37151181
[TBL] [Abstract][Full Text] [Related]
16. Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study.
Pontillo G; Cocozza S; Lanzillo R; Russo C; Stasi MD; Paolella C; Vola EA; Criscuolo C; Borrelli P; Palma G; Tedeschi E; Morra VB; Elefante A; Brunetti A
AJNR Am J Neuroradiol; 2019 Jan; 40(1):99-106. PubMed ID: 30573464
[TBL] [Abstract][Full Text] [Related]
17. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
JAMA Neurol; 2022 Jul; 79(7):682-692. PubMed ID: 35575778
[TBL] [Abstract][Full Text] [Related]
18. Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
Xiang B; Brier MR; Kanthamneni M; Wen J; Snyder AZ; Yablonskiy DA; Cross AH
Mult Scler; 2022 Sep; 28(10):1515-1525. PubMed ID: 35196933
[TBL] [Abstract][Full Text] [Related]
19. Neuroinflammatory component of gray matter pathology in multiple sclerosis.
Herranz E; Giannì C; Louapre C; Treaba CA; Govindarajan ST; Ouellette R; Loggia ML; Sloane JA; Madigan N; Izquierdo-Garcia D; Ward N; Mangeat G; Granberg T; Klawiter EC; Catana C; Hooker JM; Taylor N; Ionete C; Kinkel RP; Mainero C
Ann Neurol; 2016 Nov; 80(5):776-790. PubMed ID: 27686563
[TBL] [Abstract][Full Text] [Related]
20. Ovarian aging is associated with gray matter volume and disability in women with MS.
Graves JS; Henry RG; Cree BAC; Lambert-Messerlian G; Greenblatt RM; Waubant E; Cedars MI; Zhu A; ; Bacchetti P; Hauser SL; Oksenberg JR
Neurology; 2018 Jan; 90(3):e254-e260. PubMed ID: 29273686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
